3.00
Neumora Therapeutics Inc stock is traded at $3.00, with a volume of 810.22K.
It is down -1.64% in the last 24 hours and up +53.06% over the past month.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
See More
Previous Close:
$3.05
Open:
$3.09
24h Volume:
810.22K
Relative Volume:
0.52
Market Cap:
$509.82M
Revenue:
-
Net Income/Loss:
$-236.30M
P/E Ratio:
-2.0502
EPS:
-1.4633
Net Cash Flow:
$-208.07M
1W Performance:
-15.49%
1M Performance:
+53.06%
6M Performance:
+78.57%
1Y Performance:
+109.79%
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Name
Neumora Therapeutics Inc
Sector
Industry
Phone
(857) 760-0900
Address
260 ARSENAL PLACE, SUITE 1, WATERTOWN
Compare NMRA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
NMRA
Neumora Therapeutics Inc
|
3.00 | 518.31M | 0 | -236.30M | -208.07M | -1.4633 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-17-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-12-26 | Initiated | Leerink Partners | Outperform |
| Dec-01-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Oct-27-25 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-16-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Apr-02-25 | Downgrade | BofA Securities | Buy → Underperform |
| Mar-10-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-07-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-07-25 | Downgrade | Stifel | Buy → Hold |
| Jan-02-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-05-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-01-24 | Initiated | H.C. Wainwright | Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Jul-08-24 | Initiated | Mizuho | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Hold |
| Oct-10-23 | Initiated | BofA Securities | Buy |
| Oct-10-23 | Initiated | Guggenheim | Buy |
| Oct-10-23 | Initiated | JP Morgan | Overweight |
| Oct-10-23 | Initiated | RBC Capital Mkts | Outperform |
| Oct-10-23 | Initiated | Stifel | Buy |
| Oct-10-23 | Initiated | William Blair | Outperform |
View All
Neumora Therapeutics Inc Stock (NMRA) Latest News
Neumora Therapeutics Inc (NMRA) Sheds More Light on Phase 1b Study of NMRA-511 - Finviz
Esperion Therapeutics Inc (ESPR) Strengthens Business Outlook Amid Strategic Agreements - Bitget
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
12 Best NASDAQ Penny Stocks to Buy According to Analysts - Insider Monkey
Neumora Therapeutics (NASDAQ:NMRA) Shares Gap DownTime to Sell? - MarketBeat
GSA Capital Partners LLP Cuts Position in Neumora Therapeutics, Inc. $NMRA - MarketBeat
AlphaCore Capital LLC Has $1.16 Million Stock Holdings in Neumora Therapeutics, Inc. $NMRA - MarketBeat
Neumora Therapeutics (NMRA) Projected to Post Earnings on Monday - MarketBeat
Neumora cut to Hold at Stifel after J&J’s VENTURA exit - MSN
Can Neumora Therapeutics Inc. stock withstand economic slowdownJuly 2025 Snapshot & Weekly Setup with High ROI Potential - mfd.ru
Risk Recap: Is Telomir Pharmaceuticals Inc stock a buy or sellFed Meeting & Smart Allocation Stock Tips - baoquankhu1.vn
Neumora Therapeutics CFO Milligan sells $5119 in shares By Investing.com - Investing.com Australia
Neumora Therapeutics CFO Milligan sells $5119 in shares - Investing.com South Africa
Top Neumora Executives Quietly Cash Out in Coordinated Stock Sell-Off - TipRanks
Insider Sell Alert: Michael Milligan Sells Shares of Neumora The - GuruFocus
Neumora Therapeutics (NASDAQ:NMRA) Insider Paul Berns Sells 9,819 Shares - MarketBeat
Insider Selling: Neumora Therapeutics (NASDAQ:NMRA) Insider Sells 6,165 Shares of Stock - MarketBeat
Trading Recap: Will Neumora Therapeutics Inc stock go up in YEARTake Profit & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Neumora Therapeutics advances in novel brain-penetrant therapies - Traders Union
Neumora Therapeutics (NASDAQ:NMRA) Hits New 12-Month High Following Analyst Upgrade - MarketBeat
William Blair upgrades Neumora Therapeutics (NMRA) - MSN
William Blair Upgrades Neumora Therapeutics (NMRA) - Nasdaq
Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment - Benzinga
Neumora Therapeutics Shares Rise After William Blair Upgrade - marketscreener.com
Neumora Therapeutics (NASDAQ:NMRA) Shares Gap Up After Analyst Upgrade - MarketBeat
William Blair Upgrades Neumora Therapeutics to Outperform From Market Perform - marketscreener.com
Neumora Therapeutics (NASDAQ:NMRA) Rating Increased to Outperform at William Blair - MarketBeat
Will Neumora Therapeutics Inc. stock go up in YEAR2025 Trading Recap & Fast Entry Momentum Trade Alerts - mfd.ru
Neumora Therapeutics Highlights NMRA-511 AD Agitation Signal, Maps Higher-Dose Plan for 2026 - MarketBeat
NMRA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Neumora Therapeutics (NASDAQ:NMRA) Sets New 1-Year HighHere's What Happened - MarketBeat
Neumora Therapeutics, Inc. (NMRA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026Slideshow (NASDAQ:NMRA) 2026-02-12 - Seeking Alpha
NMRA: NMRA-511 shows strong efficacy in Alzheimer's agitation; pipeline and cash runway support growth - TradingView
Differentiated NMRA-511 Efficacy and Safety in Alzheimer’s Agitation Support Buy Rating on Neumora - TipRanks
Does Neumora Therapeutics’ (NMRA) Guggenheim Spotlight Recast Its Core Neuroscience Investment Narrative? - simplywall.st
Neumora Therapeutics, Inc. Presents NMRA-511 Efficacy at Biotech Summit - TradingView
Neumora Therapeutics (NASDAQ:NMRA) Trading Up 25.3%What's Next? - MarketBeat
3 Promising Penny Stocks With Market Caps Up To $400M - simplywall.st
Neumora gains after early-stage trial results for Alzheimer’s product - MSN
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of "Hold" by Analysts - MarketBeat
Resistance Check: Should I buy Neumora Therapeutics Inc stock nowPortfolio Update Report & Expert Verified Movement Alerts - baoquankhu1.vn
Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Short Interest in Neumora Therapeutics, Inc. (NASDAQ:NMRA) Drops By 20.2% - MarketBeat
ETF Watch: Will Neumora Therapeutics Inc stock go up in YEAR2025 Earnings Surprises & Consistent Return Investment Signals - baoquankhu1.vn
FY2030 Earnings Estimate for NMRA Issued By HC Wainwright - MarketBeat
Stop Loss: Can QMMM Holdings Limited navigate macro headwindsQuarterly Market Review & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Investment Review: What makes SZZLU stock attractive todayInflation Watch & Weekly High Return Forecasts - baoquankhu1.vn
NMRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Targets Report: Can AZEK continue delivering strong returnsQuarterly Profit Report & AI Based Trade Execution Alerts - baoquankhu1.vn
Volume Report: Is Neumora Therapeutics Inc showing insider buying2025 Fundamental Recap & Weekly Return Optimization Alerts - baoquankhu1.vn
Earnings Beat: Should I hold or sell SPCE nowMarket Weekly Review & Fast Gain Stock Trading Tips - baoquankhu1.vn
Neumora Therapeutics Inc Stock (NMRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neumora Therapeutics Inc Stock (NMRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pinto Joshua | President |
Feb 17 '26 |
Sale |
3.54 |
5,967 |
21,093 |
57,783 |
| BERNS PAUL L | See Remarks |
Feb 17 '26 |
Sale |
3.51 |
9,819 |
34,459 |
7,395,185 |
| Milligan Michael Lee | See Remarks |
Feb 17 '26 |
Sale |
3.56 |
1,436 |
5,119 |
21,034 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):